Tumor cell surface ligand (null)

Tumor cell surface ligands refer to membrane-bound molecules, including proteins, glycoproteins, and other antigens, that are expressed on the surface of cancer cells. These ligands mediate interactions with the tumor microenvironment, regulate processes such as immune escape, signaling, and metastasis, and serve as primary targets for the development of cancer therapeutics. Antibody-coated tumor cells typically result from treatment with monoclonal antibodies or antibody-conjugates designed to bind specific surface antigens, enabling targeted immune-mediated destruction or delivery of cytotoxic agents. Contemporary strategies employ combinatorial screening of peptide libraries or design of synthetic ligands to rationally target tumor surface molecules and profile tumor heterogeneity. For clinical and research purposes, specific ligands such as PD-L1, HER2, EGFR ligands, and chemokine ligands are characterized and targeted; however, the phrase as provided is too broad for unique structural identification

Other names

Tumor surface ligandCancer cell surface ligandTumor-associated antigenCancer cell surface marker

Direct cytotoxicity (antibody-dependent cell-mediated cytotoxicity via antibody-coated cells) Immune checkpoint blockade (inhibition of immune suppressive ligand-receptor pairs) Blockade of proliferative signaling pathways Targeted drug delivery using cell surface ligands as "address" molecules